Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;32(3):252-3.
doi: 10.1097/INF.0b013e3182745dba.

Prevalence of human leukocyte antigen-B*5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use

Thanyawee Puthanakit  1 , Torsak Bunupuradah, Pope Kosalaraksa, Ung Vibol, Rawiwan Hansudewechakul, Sasiwimol Ubolyam, Tulathip Suwanlerk, Suparat Kanjanavanit, Chaiwat Ngampiyaskul, Jurai Wongsawat, Wicharn Luesomboon, Saphonn Vonthanak, Jintanat Ananworanich, Kiat Ruxrungtham; PREDICT Study Group
Affiliations

Prevalence of human leukocyte antigen-B*5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use

Thanyawee Puthanakit et al. Pediatr Infect Dis J. 2013 Mar.

Abstract

Human leukocyte antigen (HLA)-B*5701 allele is associated with abacavir hypersensitivity. Limited data among Asians showed lower rates of HLA-B*5701 compared with Caucasians. In 296 children with HIV in Thailand and Cambodia, the prevalence of HLA-B*5701 was 4.0% (95% confidence interval: 1.6-8.0%) among Thai and 3.4% (95% confidence interval: 0.9-8.5%) among Cambodian children. HLA-B*5701 carriage is not uncommon among Thai and Cambodian children; it is close to the prevalence found in European and higher than the prevalence found in East Asian and African studies.

PubMed Disclaimer

Conflict of interest statement

The authors have no other funding or conflicts of interest to disclose.

Similar articles

See all similar articles

Cited by

References

    1. Green H, Gibb DM, Walker AS, et al. Paediatric European Network for the Treatment of AIDS (PENTA) Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS. 2007;21:947–955. - PubMed
    1. Welch S, Sharland M, Lyall EG, et al. PENTA Steering Committee. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med. 2009;10:591–613. - PubMed
    1. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23:1603–1614. - PubMed
    1. Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS. 2005;19:979–981. - PubMed
    1. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359:1121–1122. - PubMed

Publication types